Misleading graph or interpretation? Easier to blame the surgeons: TAVR durability trials at TCT 2023
TAVR durability is of key importance. At TCT 2023 two new longer-term follow-up reports were published: PARTNER 3 at 5 years and Evolut Low-Risk at 4 years. A great friend … Continue reading Misleading graph or interpretation? Easier to blame the surgeons: TAVR durability trials at TCT 2023
CARDiOmics Club 